Papers

Peer-reviewed
Jun, 2021

A Case of Metastatic Fumarate Hydratase-Deficient-like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab.

Acta medica Okayama
  • Takanori Sekito
  • Atsushi Takamoto
  • Yasuyuki Kobayashi
  • Masao Mitsui
  • Shogo Watari
  • Risa Kubota
  • Takuya Sadahira
  • Takehiro Iwata
  • Shingo Nishimura
  • Kohei Edamura
  • Tomoko Sako
  • Motoo Araki
  • Masami Watanabe
  • Toyohiko Watanabe
  • Rei Shibata
  • Daisuke Ennishi
  • Yasutomo Nasu
  • Display all

Volume
75
Number
3
First page
397
Last page
402
Language
English
Publishing type
Research paper (scientific journal)
DOI
10.18926/AMO/62237

We report a 62-year-old male with metastatic fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) without fumarate hydratase (FH) mutation (FH-deficient-like RCC). The International Metastatic RCC Database Consortium risk score was intermediate, and immunotherapy with nivolumab and ipilimumab (Ipi/ Nivo) was initiated. Four cycles of Ipi/Nivo and 5 cycles of nivolumab resulted in a complete response of the metastases. Hypophysitis occurred as an immune-related adverse event after four cycles of Ipi/Nivo. The prognosis of patients with FH-deficient RCC is generally poor. Few reports of FH-deficient RCC successfully treated with Ipi/Nivo have been published. Ipi/Nivo can be effective for treating FH-deficient RCC.

Link information
DOI
https://doi.org/10.18926/AMO/62237
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34176946
ID information
  • DOI : 10.18926/AMO/62237
  • Pubmed ID : 34176946

Export
BibTeX RIS